Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose (PRADO)
A Pan-European Randomized, Parallel Group, Two-arm Placebo-controlled, Double-blind Multicenter Study of Rimonabant 20mg Once Daily in the Treatment of Abdominally Obese Patients With Impaired Fasting Blood Glucose With or Without Other Comorbidities
Sponsor: Sanofi
Terminated
EMEA recommendation to suspend Acomplia marketing authorisation
A PHASE3 clinical study on Obesity, this trial is terminated or withdrawn. The trial is conducted by Sanofi and has accumulated 6 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Dec 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Bratislava, Slovakia , Bromma, Sweden , Budapest, Hungary , Cairo, Egypt , Col. Coyoacan, Mexico , Diegem, Belgium , Dublin, Ireland , Geneva, Switzerland , Gouda, Netherlands and 17 more locations